Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tacere Therapeutics Inc.

Division of Benitec Biopharma Ltd.
www.tacerebio.com

Latest From Tacere Therapeutics Inc.

Benitec May Change HCV Paradigm Again With Single-Dose, DNA-Directed RNAi

The Australian biotech recently got FDA authorization to move its first (dd)RNA candidate, TT-034, into clinical development for hepatitis C. Dosing in a 14-patient, five-cohort, Phase I/IIa study will begin in mid-March and produce final data in about 18 months.

BioPharmaceutical Clinical Trials

Benitec May Change HCV Paradigm Again With Single-Dose, DNA-Directed RNAi

The Australian biotech got FDA authorization in January to move its first (dd)RNA candidate, TT-034, into clinical development for hepatitis C. Dosing in a 14-patient, five-cohort, Phase I/IIa study will begin in mid-March and produce final data in about 18 months.

BioPharmaceutical Australia

Deals Shaping The Medical Industry, December 2012

Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Bionomics links with Chinese firm for RNAi approach to hepatitis B

The Australian gene silencing company Benitec has linked up with China's Biomics Biotechnologies to develop an RNA interference-based treatment for chronic hepatitis B infection.

Infectious Diseases China
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Benitec Biopharma Ltd.
  • Senior Management
  • Sara M Hall, Pres. & CEO
    Michael J Catelani, Chmn., Pres. & CFO
    David Suhy, PhD, CSO
  • Contact Info
  • Tacere Therapeutics Inc.
    Phone: (408) 960-2205
    5941 Optical Ct.
    San Jose, CA 95138
    USA
UsernamePublicRestriction

Register